The U.S. Food and Drug Administration (FDA) has granted approval for Dupixent (generic name dupilumab) to be used as a treatment for allergic fungal rhinosinusitis (AFRS) in adults and in children aged six years and older who have a history of sinus or nasal surgery. This decision marks a significant advancement in care for patients who suffer from this difficult‑to‑treat chronic sinus condition, offering a targeted option that can help reduce symptoms, decrease the need for repeat surgery or oral steroids, and improve quality of life.
This approval expands the list of indications for Dupixent, bringing the total to nine conditions related to type 2 inflammation that the medicine is now approved to treat. These conditions include sino‑nasal, skin, gut, and respiratory diseases affecting a broad range of patients from young children to elderly adults.
In this blog, we will explain what allergic fungal rhinosinusitis is, how Dupixent works, the clinical evidence supporting its approval, what the approval means for patients and clinicians, and safety considerations. We also address why this represents a major step forward for many who previously had limited options.
Allergic fungal rhinosinusitis, commonly known as AFRS, is a type of chronic sinus inflammation triggered by an exaggerated allergic reaction to common fungi present in the environment. Unlike routine sinus infections caused by bacteria or viruses, AFRS results from the immune system’s hypersensitivity to fungal spores, especially in warm, humid regions where these spores are abundant.
AFRS can cause extensive inflammation and thick mucus accumulation in the sinuses, leading to blocked nasal passages, persistent congestion, nasal polyps, and a significant loss of smell. For many patients, these symptoms are chronic, significantly affecting daily functioning and wellbeing.
In severe forms, AFRS can lead to bone erosion around the sinus cavities and noticeable changes in facial structure, and it often does not respond satisfactorily to traditional treatment options. Standard care typically includes surgical removal of obstructive tissue and prolonged courses of systemic corticosteroids. Even with these measures, recurrence rates are high.
Dupixent is a biologic medicine given via injection under the skin. It targets key pathways in the immune system by blocking interleukin‑4 (IL‑4) and interleukin‑13 (IL‑13) signaling, two proteins that play a major role in type 2 inflammation.
Type 2 inflammation is a central driver not only in AFRS but also in several other chronic inflammatory conditions such as:
By modulating these inflammatory pathways, Dupixent can reduce inflammation, decrease mucus production, and help restore normal sinus function.
Importantly, Dupixent is not an immunosuppressant in the traditional sense. Instead, it selectively blocks specific immune signals that drive disease, helping to control symptoms while maintaining overall immune function.
The FDA’s decision to approve Dupixent for AFRS was based on results from a Phase 3 clinical study called LIBERTY‑AFRS‑AIMS. This trial involved 62 participants aged 6 years or older with a confirmed diagnosis of AFRS, all of whom had undergone prior sino‑nasal surgery.
Participants were randomly assigned to receive either Dupixent or a placebo. The trial primary outcome was a comparison of sinus inflammation on CT scans after 52 weeks, using a validated scoring system. Secondary outcomes included patient‑reported nasal congestion, changes in nasal polyp size, sense of smell, and the need for surgery or systemic steroids.
The study showed that patients treated with Dupixent experienced significant improvements compared with placebo:
These results demonstrate that Dupixent not only helps control symptoms but also affects key elements of superficial inflammation and disease progression in AFRS.
Furthermore, the safety profile observed in this trial was consistent with what had previously been documented for Dupixent in other types of chronic inflammatory disease. Common side effects included injection site reactions and eye inflammation, which were generally manageable.
Before this FDA approval, patients with AFRS faced limited options. Standard treatments like surgery and corticosteroids worked inconsistently for many, and disease relapse was common. The approval of Dupixent introduces a disease‑modifying option that helps reduce inflammation and supports longer‑term improvement.
For clinicians, this means an additional tool in managing a condition that previously relied heavily on invasive interventions and broad‑spectrum systemic steroids. Reducing reliance on continuous steroid use also has benefits, as systemic steroids can carry significant side effects when used long term.
For patients, this approval offers new hope of:
This is especially meaningful for children, for whom chronic steroid exposure can have long‑term developmental impacts.
Dupixent is administered by injection that can be done in a clinic or, after proper guidance, by a caregiver at home. Dosage is weight‑based in pediatric patients and follows established guidelines in adults.
In adults, the typical dose is 300 mg every two weeks. In children, dosing is tailored based on weight and age. Caregivers should be trained by a healthcare professional before attempting home administration. Children aged 12 years and older should receive injections under supervision of an adult.
It is essential to follow all instructions provided by the prescribing clinician, and patients should keep regular follow‑up appointments to monitor response and any potential side effects.
Like all medicines, Dupixent can cause side effects. Common side effects observed across indications include:
More serious allergic reactions are rare but can occur. Any signs of severe allergic response such as difficulty breathing, swelling of the face or tongue, or rash should be addressed immediately with emergency care.
Patients with existing eye issues or those planning to receive live vaccines should discuss these factors with their healthcare provider prior to starting Dupixent.
Because Dupixent affects immune signaling pathways, individuals should inform their physician of all current medications and medical conditions before treatment begins.
With this approval, Dupixent continues to demonstrate its role as a leading biologic in managing type 2 inflammatory diseases. Its effectiveness across multiple indications highlights the central role of IL‑4 and IL‑13 pathways in chronic inflammatory disorders.
Regeneron Pharmaceuticals and Sanofi, the developers of Dupixent, are continuing research into additional potential uses of dupilumab in conditions driven by type 2 inflammation or allergic processes. This may in future expand treatment options for conditions where effective therapies remain limited.
In addition, regulatory submissions are planned or underway in other regions around the world, which could expand access to Dupixent for patients with AFRS outside the United States.
The FDA approval of Dupixent for allergic fungal rhinosinusitis in patients aged six years and older is a meaningful advancement in the treatment of this chronic and often frustrating condition. This decision is supported by high‑quality clinical evidence showing clear benefits in symptom control, reduction of inflammation, improved sense of smell, and lowered need for surgery or systemic steroids.
Patients living with AFRS now have a targeted therapy that can address underlying inflammatory mechanisms rather than only managing symptoms with surgery or broad steroids. For doctors, this provides a more precise and evidence‑based option that aligns with modern immunology‑driven care.
As research continues and awareness increases, people with AFRS can look forward to improved outcomes and more personalized approaches to care.
This blog is based on the FDA approval announcement and clinical study data provided by Regeneron Pharmaceuticals, Inc. and Sanofi. Data includes Phase 3 trial outcomes, regulatory details, and official safety information.
The information presented in this article is for educational and informational purposes only. It is not medical advice and should not be used as a substitute for professional consultation, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider regarding any medical condition or medication questions. The author and publisher do not assume responsibility for any reliance on the information contained herein.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.